Skip to main content
NewslettersWatchlist

Biogen Inc(BIIB-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low173.66
Day High179.20
Open:176.87
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
Motley Fool
Biogen (BIIB) Q3 2024 Earnings Call Transcript
GlobeNewswire
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
GlobeNewswire
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
GlobeNewswire
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
GlobeNewswire
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
GlobeNewswire
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
Motley Fool
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
GlobeNewswire
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
MarketBeat
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
GlobeNewswire
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
GlobeNewswire
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
Motley Fool
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
GlobeNewswire
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
GlobeNewswire
Biogen Board Appoints Two New Independent Directors
GlobeNewswire
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
Motley Fool
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
Motley Fool
Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs
PressReach
New Study Reveals How Classical Music Could Revolutionize Depression Care
Motley Fool
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.
Newswire.ca
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
Motley Fool
Biogen (BIIB) Q2 2024 Earnings Call Transcript

Profile

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.